Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
¥ 126
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Chordia is focused on the oncology area, with its target areas ranging from exploratory research to Proof of Concept (POC). For subsequent business development, we will build a system that allows us to make the best choices for maximizing corporate value, such as out-licensing and joint development and sales.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Data is available to registered users only
Buy
Sell